Department of Pulmonary and Critical Care Medicine, National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine; Chinese Academy of Medical Sciences; Center of Respiratory Medicine; China-Japan Friendship Hospital, Beijing, People’s Republic of China
Auto-generated profile, based on publicly available information
Jing Geng
Department of Pulmonary and Critical Care Medicine, National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine; Chinese Academy of Medical Sciences; Center of Respiratory Medicine; China-Japan Friendship Hospital, Beijing, People’s Republic of China
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic interstitial pneumonia. And, oxidation/antioxidant imbalance plays an important role in the progress of IPF. Fullerene is considered to be a novel “structural” antioxidant. This study aimed to explore if water-soluble C60 (C60(OH)22) can exhibit antifibrotic activity in its antioxidant role. Methods: Healthy C57BL/6J mice were randomly grouped and induced pulmonary fibrosis by intratracheal injection of bleomycin. Results: The survival rate of mice was observed and found that 10mg/kg was the optimal dose of water-soluble C60 for pulmonary fibrosis. We observed that water-soluble C60 can alleviate the severity of pulmonary fibrosis by observing the chest computed tomography, pulmonary pathology, and content of collagen, alpha smooth muscle actin and fibronectin in lung. Compared with bleomycin group, ROS, the content of TNF-α in BALF, and the number of fibroblasts was significantly decreased and the number of type Ⅱ alveolar epithelial cells was increased after treatment with C60. Conclusion: Therefore, thanks to its powerful antioxidant action, water-soluble C60 can reduce the severity of pulmonary fibrosis induced by bleomycin in mice.
1 June 2023 in Pharmacogenomics and Personalized Medicine
Background: Coal worker’s pneumoconiosis (CWP) is a chronic occupational disease mainly caused by coal dust inhalation in miners. This study aimed to investigate the clinical value of Osteopontin (OPN), KL-6, Syndecan-4 and Gremlin-1 as serum biomarkers in CWP. Patients and Methods: We integrated reported lung tissues transcriptome data in pneumoconiosis patients with silica-exposed alveolar macrophage microarray data to identify four CWP-associated serum biomarkers. The serum concentrations of Osteopontin, Krebs von den Lungen-6 (KL-6), Syndecan-4 and Gremlin-1 were measured in 100 healthy controls (HCs), 100 dust-exposed workers (DEWs) and 200 patients of CWP. Receiver operating characteristic (ROC) curve analysis was used to determine the sensitivity, specificity, cut-off value and area under the curve (AUC) value of biomarkers. Results: The pulmonary function parameters decreased sequentially, and the serum OPN, KL-6, Syndecan-4 and Gremlin-1 concentrations were increased sequentially among the HC, DEW and CWP groups. Among all participants, multivariable analysis revealed that these four biomarkers were negatively correlated with the pulmonary function parameters (all p< 0.05). Compared with HCs, patients with higher OPN, KL-6, Syndecan-4 and Gremlin-1 had higher risk for CWP. The combination of OPN, KL-6, and Syndecan-4 can improve the diagnostic sensitivity and specificity of CWP patients differentiated from HCs or DEWs. Conclusion: OPN, KL-6 and Syndecan-4 are novel biomarkers that can be used for CWP auxiliary diagnosis. The combination of three biomarkers can improve the diagnostic values of CWP.
1 August 2025 in International Journal of General Medicine
Objective: To assess imaging quantitative markers on baseline High-resolution computed tomography (HRCT) for predicting rapid progression (RP) and adverse events in anti-synthetase syndrome associated interstitial lung disease (ASS-ILD) and anti-MDA5-positive dermatomyositis-associated interstitial lung disease (MDA5-ILD). Methods: This retrospective study analyzed 511 patients (ASS-ILD: n=356, median age=56 years; MDA5-ILD: n=155, median age=50 years) between Jan 2016 and Dec 2021. RP was defined as pulmonary function, image, or symptom aggravation within 3 months of initial presentation. Adverse events (death/intensive care) were recorded. Deep learning quantified ground-glass opacity (GGO) and consolidation volumes/percentages on baseline HRCT. Multivariable logistic and Cox regression adjusted for confounders (age, gender, smoking status, body mass index, fibrosis, and treatment). No multiple comparisons were conducted since this is an explorable study. Results: RP occurred in 34.8% (124/356) of ASS-ILD and 44.5% (69/155) of MDA5-ILD patients. Elevated GGO/consolidation volumes and percentages independently predicted RP in patients with ASS-ILD (adjusted odd ratio=1.63, 95% confidence interval:1.25– 2.12, P< 0.001), but not in patients with MDA5-ILD. During median follow-up (ASS-ILD: 4.45 years; MDA5-ILD: 4.05 years), RP patients showed higher mortality versus patients without RP (hazard ratio=4.12, P< 0.001). Increased baseline GGO/consolidation metrics predicted adverse events in patients with ASS-ILD or MDA5-ILD (P< 0.01). Conclusion: GGO and consolidation quantification on baseline HRCT can provide clinically actionable predictors to identify patients with ASS-ILD at high-risk for RP, and to stratify adverse event risks across ASS/MDA5-ILD regardless of RP status, enabling early intervention.